Study identifies pathway involved in suppressing KRAS G12D-mutant pancreatic cancer
Pancreatic cancer is notoriously aggressive and difficult to treat, underscoring the need for more effective therapeutic targets. Research led by Jie Fu, Ph.D., Jianhua Ling, Ph.D., and Paul Chiao, Ph.D., previously showed that apoptosis, or cell death, resistance in KRAS G12D-mutant pancreatic cancer was accelerated by deleting the Plk3 tumor suppressor, but the regulatory mechanism of Plk3 activation remains unknown. To provide further insights, the researchers examined the role of Plk3 in KRAS G12D-mutant pancreatic cancer models. They...